Australia's "Fourth Hurdle" drug review comparing costs and benefits holds lessons for the United States

Health Affairs

Volumn 32, Issue 4, 2013, Pages 778-787

  Lopert, Ruth ^a,b   Elshaug, Adam G ^c,d  

^a THERAPEUTIC GOODS ADMINISTRATION   (Australia)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d Commonwealth Fund ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; AUSTRALIA; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG MARKETING; ECONOMIC EVALUATION; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HEALTH PROGRAM; UNITED STATES;

ADVISORY COMMITTEES; AUSTRALIA; COST-BENEFIT ANALYSIS; DELIVERY OF HEALTH CARE; DRUG COSTS; HEALTH EXPENDITURES; HUMANS; PHARMACOPOEIAS AS TOPIC; PRESCRIPTION DRUGS; UNITED STATES;

EID: 84877949139     PISSN: 02782715     EISSN: 15445208     Source Type: Journal    
DOI: 10.1377/hlthaff.2012.1058     Document Type: Article

References (35)

1. Ayanian JZ, Van der Wees PJ. Tackling rising health care costs in Massachusetts. N Engl J Med. 2012;367(9):790-3.
2. Community Manager. The escalating race for evidence in drug reimbursement: price versus value. Health Economics Digest [serial on the Internet]. 2012 Jul 25 [cited 2013 Mar 1]. Available from: http://www.healtheconomicsdigest.com/evidence-in-drug-reimbursement/
3. Squires DA. The U.S. health system in perspective: a comparison of twelve industrialized nations [Internet]. New York (NY): Commonwealth Fund; 2011 Jul [cited 2013 Mar 1]. (Issues in International Health Policy). Available from: http://www.commonwealthfund.org/~/media/Files/Publications/Issue%20Brief/2011/Jul/1532_Squires_US_hlt_sys_comparison_12_nations_intl_brief_v2.pdf
4. Woolf SH, Aron L, editors. U.S. health in international perspective: shorter lives, poorer health. Washington (DC): National Academies Press; 2013.
5. Taylor RS, Drummond MF, Salkeld G, Sullivan SD. Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle. BMJ. 2004;329(7472): 972-5.
6. Australian Department of Health and Ageing. National medicines policy: 2000 [Internet]. Canberra: Commonwealth of Australia; 1999 [cited 2013 Mar 1]. Available from: http://tinyurl.com/9zclbge
7. Australian Department of Health and Ageing. About the PBS: what are the current patient fees and charges? [Internet]. Canberra: Commonwealth of Australia; [cited 2013 Mar 1]. Available from: http://www.pbs.gov.au/info/about-thepbs#What_are_the_current_patient_fees_and_charges
8. Dickson M, Hurst J, Jacobzone S. Survey of pharmacoeconomic assessment activity in eleven countries [Internet]. Paris: Organization for Economic Cooperation and Development; 2003 May 16 [cited 2013 Mar 1]. (OECD Health Working Papers No. 4). Available from: http://www.oecd.org/dataoecd/27/25/2955828.pdf
9. Birkett DJ, Mitchell AS, McManus P. A cost-effectiveness approach to drug subsidy and pricing in Australia. Health Aff (Millwood). 2001;20(3):104-14.
10. Australian Department of Health and Ageing. Pharmaceutical Benefits Advisory Committee [Internet]. Canberra: Commonwealth of Australia; [last modified 2007 Nov 13; cited 2013 Mar 1]. Available from: http://www.health.gov.au/internet/main/publishing.nsf/Content/health-pbs-general-listingcommittee3.htm
11. Lopert R. Evidence-based decisionmaking within Australia's Pharmaceutical Benefits Scheme [Internet]. New York (NY): Commonwealth Fund; 2009 Jul [cited 2013 Mar 1]. (Issue Brief). Available from: http://www.commonwealthfund.org/Publications/Issue-Briefs/2009/Jul/Decision-Making-Within-Australia.aspx
12. Australian Department of Health and Ageing. PBAC guidelines [Internet]. Canberra: Commonwealth of Australia; [cited 2013 Mar 1]. Available for download from: http://www.pbs.gov.au/info/industry/listing/elements/pbacguidelines
13. Wilensky GR. Cost-effectiveness information: yes, it's important, but keep it separate, please! Ann Intern Med. 2008;148(12):967.
14. Montopoli B. Obama: "why not pay half price?" CBS News [serial on the Internet]. 2009 Jul 23 [cited 2013 Mar 8]. Available from: http://www.cbsnews.com/8301-503544_162-5181448-503544/obama-why-notpay-half-price-/
15. Pearson SA, Ringland CL, Ward RL. Trastuzumab and metastatic breast cancer: trastuzumab use in Australia-monitoring the effect of an expensive medicine access program. J Clin Oncol. 2007;25(24): 3688-93.
16. Australian Department of Health and Ageing. Framework for the introduction of a Managed Entry Scheme for submissions to the Pharmaceutical Benefits Advisory Committee [Internet]. Canberra: Commonwealth of Australia; 2011 Feb 18 [cited 2013 Mar 1]. Available from: http://www.pbs.gov.au/info/publication/factsheets/shared/framework-for-introduction-ofmanaged-entry-scheme-for-PBACsubmissions
17. Gafni A, Birch S. Inclusion of drugs in provincial benefit programs: should "reasonable decisions" lead to uncontrolled growth in expenditures? CMAJ. 2003;168(7):849-51.
18. Danzon PM, Furukawa MF. Prices and availability of biopharmaceuticals: an international comparison. Health Aff (Millwood). 2006;25(5): 1353-62.
19. Roughead EE, Lopert R, Sansom LN. Prices for innovative pharmaceutical products that provide health gain: a comparison between Australia and United States. Value Health. 2007; 10(6):514-20.
20. Strech D, Persad G, Marckmann G, Danis M. Are physicians willing to ration health care? Conflicting findings in a systematic review of survey research. Health Policy. 2009; 90(2-3):114.
21. Economist Intelligence Unit. Benchmarking study of the characteristics of the Australian and international pharmaceuticals industries: final report [Internet]. New York (NY): The Unit; 2005 Sep [cited 2013 Mar 1]. Available from: http://www.qctn.com.au/Portals/0/Main_Body_Economist%20Benchmarking%20Report_Pharma.pdf
22. Wilson A, Cohen J. Patient access to new cancer drugs in the United States and Australia. Value Health. 2011;14(6):944-52.
23. Gorey KM, Luginaah IN, Holowaty EJ, Zou G, Hamm C, Balagurusamy MK. Mediation of the effects of living in extremely poor neighborhoods by health insurance: breast cancer care and survival in California, 1996 to 2011. Int J Equity Health. 2013;12(1):6.
24. Lu Y, Hernandez P, Abegunde D, Edeger T. The world medicines situation. 3rd ed. Geneva:World Health Organization; 2011. p. 16.
25. Berry SR, Bell CM, Ubel PA, Evans WK, Nadler E, Strevel EL, et al. Continental divide? The attitudes of US and Canadian oncologists on the costs, cost-effectiveness, and health policies associated with new cancer drugs. J Clin Onc. 2010;28(27): 4149-53.
26. Ginsburg JA, Kline M, Doherty RB. How can our nation conserve and distribute health care resources effectively and efficiently? [Internet]. Philadelphia (PA): American College of Physicians; 2011 Jan 27 [cited 2013 Mar 1]. (Position Paper). Available from: http://www.acponline.org/advocacy/where_we_stand/policy/health_care_resources.pdf
27. Oregon Health and Science University. Drug Effectiveness Review Project (DERP) [home page on the Internet]. Portland (OR): OHSU; [cited 2013 Mar 1]. Available from: http://www.ohsu.edu/xd/research/centers-institutes/evidence-based-policy-center/derp/index.cfm
28. Medicare Payment AdvisoryCommission. Report to Congress: reforming the delivery system. Washington (DC): MedPAC; 2008 Jun.
29. Bach PB, Saltz LB, Wittes RE. In cancer care, cost matters. New York Times [serial on the Internet]. 2012 Oct 14 [cited 2013 Mar 1]. Available from: http://www.nytimes.com/2012/10/15/opinion/a-hospitalsays-no-to-an-11000-a-monthcancer-drug.html?_r=0
30. Goldberg P. Zaltrap price cut in half effective immediately as Sanofi responds to criticism from oncologists. Cancer Letter [serial on the Internet]. 2012 Nov 8 [cited 2013 Mar 1]. Available for download from: http://www.cancerletter.com/articles/20121108
31. Garber AM. How the Patient-Centered Outcomes Research Institute can best influence realworld health care decision making. Health Aff (Millwood). 2011;30(12): 2243-51.
32. Song Z, Safran DG, Landon BE, Landrum MB, He Y, Mechanic RE, et al. The "Alternative Quality Contract," based on a global budget, lowered medical spending and improved quality. Health Aff (Millwood). 2012;31(8):1885-94.
33. Clement FM, Harris A, Li JJ,Yong K, Lee KM, Manns BJ. Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada. JAMA. 2009;302(13): 1437-43.
34. Academy of Managed Care Pharmacy. The AMCP Format for Formulary Submissions: version 3.0. Journal of Managed Care Pharmacy [serial on the Internet]. 2010 [cited 2013 Mar 1]. Available from: http://www.amcp.org/data/jmcp/1007_121%2019%2009(3).pdf
35. Reinhardt U. Divide et impera: protecting the growth of health care incomes (COSTS). Health Econ. 2012;21(1):41-54.